A2BR antagonist, ATL801, reduces metastases by more than 80% in mice, which is due to increased IFN-γ, IFN-inducible chemokine CXCL10, a ligand for CXCR3, and tumor-infiltrating CXCR3+ T cells (86). Here, CXCR3 is linked to neoplasm.